Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 540-551

  Violet, Marie ^a,e,f   Chauderlier, Alban ^a,e,f   Delattre, Lucie ^a,e,f   Tardivel, Meryem ^a,e,f   Chouala, Meliza Sendid ^a,e,f   Sultan, Audrey ^a,e,f   Marciniak, Elodie ^a,e,f   Humez, Sandrine ^a,e,f   Binder, Lester ^b   Kayed, Rakez ^c   Lefebvre, Bruno ^a,e,f   Bonnefoy, Eliette ^d   Buée, Luc ^a,e,f   Galas, Marie Christine ^a,e,f  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d INSERM   (France)

^e UNIV LILLE   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer; DNA damage; Hyperthermia; Methylene Blue; Oxidative stress; RNA damage; Tau; Tau oligomers

Indexed keywords

METHYLENE BLUE; OLIGOMER; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; MAPT PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA STRAND BREAKAGE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HYPERTHERMIA; IN VIVO STUDY; MOUSE; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TAUOPATHY; ANIMAL; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; FEVER; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; TAUOPATHIES; TRANSGENIC MOUSE;

ANIMALS; CELL DEATH; CELL NUCLEUS; CYTOPLASM; DISEASE MODELS, ANIMAL; DNA BREAKS; FEMALE; FEVER; HIPPOCAMPUS; HUMANS; METHYLENE BLUE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTEIN MULTIMERIZATION; RNA; TAU PROTEINS; TAUOPATHIES;

EID: 84947021770     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.09.003     Document Type: Article

References (53)

1. Akoury E., Pickhardt M., Gajda M., Biernat J., Mandelkow E., Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew. Chem. Int. Ed. Engl. 2013, 52(12):3511-3515.
2. Baddeley T.C., McCaffrey J., Storey J.M., Cheung J.K., Melis V., Horsley D., Harrington C.R., Wischik C.M. Complex disposition of methylthioninium redox forms determines efficacy in Tau aggregation inhibitor therapy for Alzheimer's disease. J. Pharmacol. Exp. Ther. 2015, 352(1):110-118.
3. Blair L.J., Nordhues B.A., Hill S.E., Scaglione K.M., O'Leary J.C., Fontaine S.N., Breydo L., Zhang B., Li P., Wang L., Cotman C., Paulson H.L., Muschol M., Uversky V.N., Klengel T., Binder E.B., Kayed R., Golde T.E., Berchtold N., Dickey C.A. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J. Clin. Invest. 2013, 123:4158-4169.
4. Borgesius N.Z., de Waard M.C., van der Pluijm I., Omrani A., Zondag G.C., van der Horst G.T., Melton D.W., Hoeijmakers J.H., Jaarsma D., Elgersma Y. Accelerated age-related cognitive decline and neurodegeneration, caused by deficient DNA repair. J. Neurosci. 2011, 31:12543-12553.
5. Bradley-Whitman M.A., Timmons M.D., Beckett T.L., Murphy M.P., Lynn B.C., Lovell M.A. Nucleic acid oxidation: an early feature of Alzheimer's disease. J. Neurochem. 2014, 128:294-304.
6. Camero S., Benítez M.J., Barrantes A., Ayuso J.M., Cuadros R., Avila J., Jiménez J.S. Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone-DNA complex. J. Alzheimers Dis. 2013, 39(3):649-660.
7. Castillo-Carranza D.L., Sengupta U., Guerrero-Muñoz M.J., Lasagna-Reeves C.A., Gerson J.E., Singh G., Estes D.M., Barrett A.D., Dineley K.T., Jackson G.R., Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 2014, 34(12):4260-4272.
8. Congdon E.E., Wu J.W., Myeku N., Figueroa Y.H., Herman M., Marinec P.S., Gestwicki J.E., Dickey C.A., Yu W.H., Duff K.E. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012, 8:609-622.
9. Cooper-Knock J., Kirby J., Ferraiuolo L., Heath P.R., Rattray M., Shaw P.J. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 2012, 8:518-530.
10. Crowe A., James M.J., Lee V.M., Smith A.B., Trojanowski J.Q., Ballatore C., Brunden K.R. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J. Biol. Chem. 2013, 288(16):11024-11037.
11. Deiana S., Harrington C.R., Wischik C.M., Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology 2009, 202:53-65.
12. Fabiszewski K.J., Volicer B., Volicer L. Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients. JAMA 1990, 263:3168-3172.
13. Flach K., Hilbrich I., Schiffmann A., Gartner U., Kruger M., Leonhardt M., Waschipky H., Wick L., Arendt T., Holzer M. Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 2012, 287:43223-43233.
14. Galas M.C., Dourlen P., Bégard S., Ando K., Blum D., Hamdane M., Buée L. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J. Biol. Chem. 2006, 28:19296-19304.
15. Gerson J.E., Castillo-Carranza D.L., Kayed R. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. ACS Chem. Neurosci. 2014, 5(9):752-769.
16. Guerrero-Muñoz M.J., Castillo-Carranza D.L., Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol. 2014, 88:468-748.
17. Hawkins B.E., Krishnamurthy S., Castillo-Carranza D.L., Sengupta U., Prough D.S., Jackson G.R., Dewitt D.S., Kayed R. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between TBI and sporadic tauopathies. J. Biol. Chem. 2013, 288(23):17042-17050.
18. Hikosou R., Kurabayashi Y., Doumoto M., Hoshitoku K., Mizushima F., Minoura K., Tomoo K., Ishida T. Effect of DNA on filament formation of tau microtubule-binding domain: structural dependence of DNA. Chem. Pharm. Bull. 2007, 55:1030-1033.
19. Hosokawa M., Arai T., Masuda-Suzukake M., Nonaka T., Yamashita M., Akiyama H., Hasegawa M. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One 2012, 7.
20. Hua Q., He R.Q. Effect of phosphorylation and aggregation on tau binding to DNA. Protein Pept. Lett. 2002, 9:349-357.
21. Jiang Q., Yang X., Liu B., Li M., Qian S., Zhao L., Zhou Z., Sun G. Hyperthermia impaired human visual short-term memory: an fMRI study. Int. J. Hyperth. 2013, 29:219-224.
22. Kampers T., Friedhoff P., Biernat J., Mandelkow E.M., Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996, 399:344-349.
23. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Clos A.L., Jackson G.R., Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 2011, 6:39.
24. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Sarmiento J., Troncoso J., Jackson G.R., Kayed R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012, 26:1946-1959.
25. Lu Y., He H.J., Zhou J., Miao J.Y., Lu J., He Y.G., Pan R., Wei Y., Liu Y., He R.Q. Hyperphosphorylation results in tau dysfunction in DNA folding and protection. J. Alzheimers Dis. 2013, 37(3):551-563.
26. Moreira P.I., Nunomura A., Nakamura M., Takeda A., Shenk J.C., Aliev G., Smith M.A., Perry G. Nucleic acid oxidation in Alzheimer disease. Free Radic. Biol. Med. 2008, 44(8):1493-1505.
27. Mufson E.J., Ward S., Binder L. Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's Disease. Neurodegener. Dis. 2013, 13(2-3):151-153.
28. Murakami K., Murata N., Noda Y., Tahara S., Kaneko T., Kinoshita N., Hatsuta H., Murayama S., Barnham K.J., Irie K., Shirasawa T., Shimizu T. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J. Biol. Chem. 2011, 286:44557-44568.
29. Necula M., Breydo L., Milton S., Kayed R., van der Veer W.E., Tone P., Glabe C.G. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007, 46(30):8850-8860.
30. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60(8):759-767.
31. Nunomura A., Tamaoki T., Motohashi N., Nakamura M., McKeel D.W., Tabaton M., Lee H.G., Smith M.A., Perry G., Zhu X. The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J. Neuropathol. Exp. Neurol. 2012, 71(3):233-241.
32. O'Leary J.C., Li Q., Marinec P., Blair L.J., Congdon E.E., Johnson A.G., Jinwal U.K., Koren J., Jones J.R., Kraft C., Peters M., Abisambra J.F., Duff K.E., Weeber E.J., Gestwicki J.E., Dickey C.A. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 2010, 5:45.
33. Patterson K.R., Remmers C., Fu Y., Brooker S., Kanaan N.M., Vana L., Ward S., Reyes J.F., Philibert K., Glucksman M.J., Binder L.I. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 2011, 286:23063-23076.
34. Racinais S., Gaoua N., Grantham J. Hyperthermia impairs short-term memory and peripheral motor drive transmission. J. Physiol. 2008, 586:4751-4762.
35. Reynolds M.R., Berry R.W., Binder L.I. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry 2005, 44:1690-1700.
36. Rojas J.C., Bruchey A.K., Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 2012, 96:32-45.
37. Schindowski K., Bretteville A., Leroy K., Bégard S., Brion J.P., Hamdane M., Buée L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006, 169:599-616.
38. Sjoberg M.K., Shestakova E., Mansuroglu Z., Maccioni R.B., Bonnefoy E. Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J. Cell Sci. 2006, 119:2025-2034.
39. Spires-Jones T.L., Friedman T., Pitstick R., Polydoro M., Roe A., Carlson G.A., Hyman B.T. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci. Lett. 2014, 562:63-68.
40. Stack C., Jainuddin S., Elipenahli C., Gerges M., Starkova N., Starkov A.A., Jové M., Portero-Otin M., Launay N., Pujol A., Kaidery N.A., Thomas B., Tampellini D., Beal M.F., Dumont M. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet. 2014, 23(14):3716-3732.
41. Sultan A., Nesslany F., Violet M., Begard S., Loyens A., Talahari S., Mansuroglu Z., Marzin D., Sergeant N., Humez S., Colin M., Bonnefoy E., Bueée L., Galas M.C. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 2011, 286:4566-4575.
42. Sutherland G.T., Chami B., Youssef P., Witting P.K. Oxidative stress in Alzheimer's disease: primary villain or physiological by-product?. Redox Rep. 2013, 18:134-141.
43. Tai H.C., Serrano-Pozo A., Hashimoto T., Frosch M.P., Spires-Jones T.L., Hyman B.T. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 2012, 181:1426-1435.
44. Takeda A., Itoyama Y., Kimpara T., Zhu X., Avila J., Dwyer B.E., Perry G., Smith M.A. Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid. Redox Signal. 2004, 6(5):888-894.
45. Tepper K., Biernat J., Kumar S., Wegmann S., Timm T., Hübschmann S., Redecke L., Mandelkow E.M., Müller D.J., Mandelkow E. Oligomer formation of tau hyperphosphorylated in cells. J. Biol. Chem. 2014, 289(49):34389-34407.
46. Van der Jeugd A., Vermaercke B., Derisbourg M., Lo A.C., Hamdane M., Blum D., Buée L., D'Hooge R. Progressive age-related cognitive decline in tau mice. J. Alzheimers Dis. 2013, 37(4):777-788.
47. Vanhelmont T., Vandebroek T., De Vos A., Terwel D., Lemaire K., Anandhakumar J., Franssens V., Swinnen E., Van Leuven F., Winderickx J. Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res. 2010, 10:992-1005.
48. Violet M., Delattre L., Tardivel M., Sultan A., Chauderlier A., Caillierez R., Talahari S., Nesslany F., Lefebvre B., Bonnefoy E., Buée L., Galas M.C. A major role for Tau in DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell. Neurosci. 2014, 8:84.
49. Ward S.M., Himmelstein D.S., Lancia J.K., Fu Y., Patterson K.R., Binder L.I. TOC1: characterization of a selective oligomeric tau antibody. J. Alzheimers Dis. 2013, 37(3):593-602.
50. Weaver C.L., Espinoza M., Kress Y., Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging 2000, 21:719-727.
51. Wei Y., Qu M.H., Wang X.S., Chen L., Wang D.L., Liu Y., Hua Q., He R.Q. Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxidation. PLoS One 2008, 3:2600.
52. Zekanowski C., Wojda U. Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 2009, 69(2):232-253.
53. Zheng-Fischhöfer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 1998, 252:542-552.